Chromium Chloride
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Chromium Chloride: Drug Repurposing Evaluation — Insufficient Data to Proceed
One-Sentence Summary
Chromium Chloride is a chromium(III)-containing compound whose approved indication could not be confirmed from available regulatory records. The TxGNN model generated no predicted indications for this compound, most likely due to an unresolved DrugBank mapping. Without a confirmed DrugBank ID, mechanism of action, or safety profile, a full repurposing evaluation cannot be completed at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established — no regulatory records found |
| Predicted New Indication | None — TxGNN returned no candidates |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (pipeline did not generate predictions) |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No repurposing candidates were generated by TxGNN for Chromium Chloride in this evaluation cycle. The most probable cause is the absence of a confirmed DrugBank ID, which prevents the compound from being linked to a node in the TxGNN knowledge graph. Without that anchor, neither the knowledge-graph (KG) method nor the deep-learning (DL) method can produce scored drug–disease pairs.
From general pharmacological knowledge, Chromium Chloride is a chromium(III) salt that has been used as a nutritional supplement ingredient to provide bioavailable trivalent chromium. Trivalent chromium is understood to participate in glucose metabolism and potentiation of insulin signalling, and has been studied — largely in the nutritional science literature — in the context of metabolic conditions such as type 2 diabetes and insulin resistance. However, this background knowledge alone is insufficient to substitute for a model-generated, evidence-weighted repurposing prediction.
Currently, detailed mechanism of action data is not available from the data sources queried. Before any repurposing hypothesis can be formally evaluated, the DrugBank ID must be confirmed, the MOA documented, and the TxGNN prediction pipeline re-run.
Clinical Trial Evidence
Currently no related clinical trials registered for this drug–indication combination.
Literature Evidence
Currently no related literature available for this drug–indication combination.
South Africa Market Information
Chromium Chloride is not currently registered with SAHPRA. No product licences were identified in the regulatory database query. There are no SAHPRA-approved dosage forms on record, and the compound does not appear on the Essential Medicines List (EML) as a registered pharmaceutical product.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note for reviewers: Two blocking data gaps were identified during evidence pack generation:
- DG001 (Blocking): SAHPRA Professional Information warnings and contraindications have not been retrieved. This prevents the S1 safety screening from being completed.
- DG002 (High): Mechanism of action data is unavailable, preventing mechanistic plausibility analysis.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model produced no repurposing predictions for Chromium Chloride, and the two most critical upstream data items — DrugBank ID and mechanism of action — are both missing. There is no actionable evidence base from which to recommend further development or clinical investigation at this time.
To proceed, the following is needed:
- Confirm DrugBank ID — Search DrugBank manually for “Chromium Chloride” (CrCl₃), “Chromic Chloride”, and related INN variants to obtain the correct DrugBank node identifier and enable knowledge graph linkage
- Resolve DG001 (Blocking) — Download and parse the SAHPRA-approved Professional Information (PI) to extract approved indications, key warnings, and contraindications
- Resolve DG002 (High) — Retrieve the full mechanism of action, pharmacodynamics, and pharmacokinetic profile via the DrugBank API once the ID is confirmed
- Re-run TxGNN pipeline — After DrugBank mapping is established, re-execute both the KG-based and DL-based prediction scripts to generate scored drug–disease candidates
- Targeted evidence search — Conduct a focused PubMed and ClinicalTrials.gov search using “chromium chloride”, “chromic chloride”, and “trivalent chromium” across disease areas identified by the re-run model (e.g., diabetes mellitus, insulin resistance, metabolic syndrome)
- Assess SAHPRA registration pathway — If repurposing evidence is subsequently identified, evaluate whether a Section 21 authorisation or a new indication application to SAHPRA would be the appropriate regulatory route, given the current zero-licence status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.